4Henderson C,Berry DA,Demetri GD,et al.Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node - positive primary breast cancer [J].J Clin Oncol,2003,21 (6):976.
5Cobleigh MA,Vogel CL,Tripathy D,et al.Multinational study of the efficacy and safety of humanized anti - HER2monoclonal antibody in women who have HER2 expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease[J].J Clin Oncol,1999,17(9):2 639.
6Pegram MD,Hsu S,Lewis G,et al.Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancer [J].Oncogene,1999,18(13) :2 241.
7Satmon DJ,Leylang Jones B,Shak S,et al.Use of chemotherapy plus a molmclonal antibody against HER - 2 for metastatic breast cancer that overexpresses HER - 2 [J].N Engl J Med ,2001,344 ( 11 ) :783.
8Seidman AD,Fornier MN,Esteva FJ,et al.Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplicationl [J].J Clin Oncol,2001,19(10) :2 587.
9Esteva FJ,Valero V,Booser D,et al.Phase Ⅱ study of weekly docetaxel and trastuzumab for patients with HER2 -overexpressing metastatic breast cancer [J] .J Clin Oncol,2002,20(7):1 800.
10Burris HA.Docetaxel(taxotere) plus trastuzumab (herceptin) in breast cancer[J] .Semin Oncol,2001,28(Supp3.1 ) :38.
